Shares in technology investment firm Angle rose on Tuesday after it said its Parsortix cell separation device had passed an important milestone.
The firm said that the device could now capture ovarian cancer cells, creating the possibility of developing an effective, non-invasive screening technique to enable the early diagnosis and monitoring of ovarian cancer.
Angle said that ovarian cancer usually had a poor prognosis and the mortality rate was disproportionately high because it lacked any clear early detection or screening test.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
This meant that most cases were not diagnosed until they have reached advanced stages.
"The successful capture and identification of cultured ovarian cancer cells added to blood is significant as it suggests that the Parsortix separation technology may work with all solid tumour cancers," said Angle's Chief Executive, Andrew Newland.
Angle said it had previously demonstrated that Parsortix could capture cultured breast cancer, prostate cancer, lung cancer and colon cancer cells added to blood.
Shares in the firm rose almost 4% following the announcement.
Who is the richest person in the world?
The top five richest people in the world have a combined net worth of $825 billion. Who takes the crown for the richest person in the world?
By Vaishali Varu Published
Top 10 stocks with highest growth over past decade - from Nvidia, Microsoft to Netflix, which companies made you the most money?
We reveal the 10 global companies with the biggest returns since 2013. One firm has posted an astonishing 9,870% return, meaning a £1,000 investment would now be worth almost £82,000.
By Ruth Emery Published